MIRAMAR, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, announced today the data presented for their tetra-valent, second-generation T-Cell Engager (“TCE”) Program based on their novel TRBC platform technology, at the SITC 40th Annual Meeting, taking pl ...